Walking for just 30 minutes a day could halve the risk of developing diabetes, researchers have found. Simple changes in diet and exercise may halt the epidemic of Type 2 diabetes, the most common ...

Tandem Diabetes Care, Inc. TNDM posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s ...

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Historical study links childhood sugar restriction with lower adult risks for diabetes and high blood pressure.

Insulet (Nasdaq:PODD) once again posted significant year-over-year growth as Omnipod revenues continue to rise.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Please verify your email address. After beating Metaphor ReFantazio and watching the curtain fall on an 80+ hour-long story, players might be wondering what to do next. Reaching the finish line ...

On Monday, Owens & Minor Inc. (NYSE:OMI) reported the third quarter of 2024 adjusted EPS of $0.42, down from $0.44 reported a ...

Beau Ehlschide, a student at Country Heights Elementary School, has been selected as a Peyton Manning Children’s Hospital ...

Shares of Alphabet, the first of the five "Magnificent Seven" megacap stocks due to report results this week, leapt 6.1% in ...

Analyst Josh Jennings of TD Cowen reiterated a Buy rating on Insulet (PODD – Research Report), retaining the price target of $264.00.